Crinetics Pharma

Crinetics Pharma, a clinical‑stage biotech, is advancing Paltusotine—an oral somatostatin receptor‑2 agonist—in Phase 3 for acromegaly and carcinoid syndrome, while expanding a pipeline of oral anti‑neuroendocrine agents and novel PTH/ACTH antagonists.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 437
HQ: San Diego

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
CRNX	Crinetics Pharma Cap: 5.5B	EQUITY	NMS	USD	US22663K1079	Active	📈